AMENDMENTS TO THE CLAIMS

1-27 (Canceled)

28. (New) A method to protect a felid from rabies infection, said method comprising parenterally administering to said felid a composition comprising a purified nucleic acid molecule encoding rabies glycoprotein G, wherein said purified nucleic acid molecule is complexed with a cationic lipid.

29. (New) The method of Claim 28, wherein said cationic lipid comprises a tetramethyltetraalkyl spermine analog lipid.

30. (New) The method of Claim 28, wherein said composition further encodes an immunomodulator.

31.(New) The method of Claim 28, wherein said felid is selected from the group consisting of domestic cats, wild cats and zoo cats.

32.(New) The method of Claim 28, wherein said felid is selected from the group consisting of domestic cats, lions, tigers, leopards, panthers, cougars, bobcats, lynx, jaguars, cheetahs and servals.

33.(New) The method of Claim 28, wherein the felid is a domestic cat.

34.(New) The method of Claim 28, wherein a single administration of said composition elicits an immune response.

35.(New) The method of Claim 28, wherein said composition enhances an immune response compared to administration of a naked DNA vaccine encoding rabies glycoprotein G

36.(New) The method of Claim 28, wherein said step of administering said composition is selected from the group consisting of intramuscular administration, intravenous administration, subcutaneous administration, intradermal administration and intraperitoneal administration.

37.(New) The method of Claim 28, wherein said step of administering effects about 75% seroconversion in a population of felids administered said purified nucleic acid molecule.

38.(New) The method of Claim 28, wherein said step of administering effects about 100% seroconversion in a population of felids administered said purified nucleic acid molecule.

39.(New) The method of Claim 28, wherein said purified nucleic acid molecule:lipid ratio is from about 1:10 to about 10:1.

40.(New) The method of Claim 28, wherein said purified nucleic acid molecule is administered in a dose of from about 75 micrograms to about 1,000 micrograms.

41.(New) The method of Claim 28, wherein said purified nucleic acid molecule is administered in a dose of not more than about 75 micrograms.

42.(New) The method of Claim 28, wherein said composition is dehydrated and subsequently rehydrated prior to administration.

43.(New) The method of Claim 28, wherein said composition further comprises an excipient.